Surrozen (SRZN) Other Non-Current Assets (2020 - 2026)
Surrozen (SRZN) recorded quarterly Other Non-Current Assets of $34000.0 in Q1 2026, down 26.09% quarter-over-quarter from $46000.0 in Q4 2025, and down 95.06% on a YoY basis from $688000.0 in Q1 2025.
Surrozen (SRZN) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Surrozen's Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $34000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 95.06% year-over-year to $34000.0; the TTM figure through Mar 2026 stood at $34000.0 (down 95.06% YoY), while the FY2025 annual figure was $46000.0, down 86.1% from the prior year.
- Other Non-Current Assets was $34000.0 for Q1 2026 at Surrozen, down from $46000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $846000.0 in Q3 2022 to a low of $34000.0 in Q1 2026.
- Historically, Other Non-Current Assets has averaged $443882.4 across 5 years, with a median of $405000.0 in 2022.
- The sharpest annual moves came in 2022 and 2026: Other Non-Current Assets jumped 108.89% in 2022, then tumbled 95.06% in 2026.
- A 5-year view of Other Non-Current Assets shows it stood at $405000.0 in 2022, then soared by 69.88% to $688000.0 in 2023, then plunged by 51.89% to $331000.0 in 2024, then slumped by 86.1% to $46000.0 in 2025, then declined by 26.09% to $34000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $34000.0 (Q1 2026), $46000.0 (Q4 2025), and $64000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | 34,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 688,000.00 |
| Mar 31, 2025 | 688,000.00 |
| Dec 31, 2024 | 331,000.00 |
| Sep 30, 2024 | 688,000.00 |
| Jun 30, 2024 | 373,000.00 |
| Mar 31, 2024 | 688,000.00 |
| Dec 31, 2023 | 688,000.00 |
| Sep 30, 2023 | 376,000.00 |
| Jun 30, 2023 | 405,000.00 |
| Mar 31, 2023 | 416,000.00 |
| Dec 31, 2022 | 405,000.00 |
| Sep 30, 2022 | 846,000.00 |
| Jun 30, 2022 | 405,000.00 |
| Mar 31, 2022 | 405,000.00 |
| Dec 31, 2021 | 549,000.00 |
| Sep 30, 2021 | 405,000.00 |
| Dec 31, 2020 | 39,000.00 |